HLA
RYTM icon

Hamilton Lane Advisors’s Rhythm Pharmaceuticals RYTM Stock Holding History

Hamilton Lane Advisors’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-34,736
Closed -$750K – 59
2019
Q3 		$750K Hold
34,736
– – 0.31% 30
2019
Q2 		$764K Hold
34,736
– – 0.38% 30
2019
Q1 		$952K Buy
+34,736
New +$998K 0.5% 34

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Hamilton Lane Advisors's RYTM Position: Q4 2019 in Review

Hamilton Lane Advisors sold out of Rhythm Pharmaceuticals (RYTM) in Q4 2019, closing a stake of 34,736 shares — an estimated $750K sold.

Hamilton Lane Advisors first reported a position in RYTM in Q1 2019 and held it in 3 quarters. The position peaked at $952K in Q1 2019. 89 funds tracked by Wall St. Rank hold RYTM as of Q4 2019.

  • Hamilton Lane Advisors reported no remaining Rhythm Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Hamilton Lane Advisors sold 34,736 Rhythm Pharmaceuticals shares in Q4 2019, an estimated $750K.
  • Hamilton Lane Advisors first reported a position in Rhythm Pharmaceuticals in Q1 2019 and held it in 3 quarters.
  • Hamilton Lane Advisors's Rhythm Pharmaceuticals position peaked at $952K in Q1 2019.
  • 89 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q4 2019.

Based on Hamilton Lane Advisors's 13F filing for Q4 2019, filed 31 Jan 2020.